Pathogenesis of placental site trophoblastic tumor may require the presence of a paternally derived X chromosome

Laboratory Investigation

Volumn 80, Issue 6, 2000, Pages 965-972

  Hui, Pei ^a   Parkash, Vinita ^a   Perkins, Archibald S ^a   Carcangiu, Maria Luisa ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; ARTICLE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENOME; HUMAN; HUMAN TISSUE; MARKER GENE; METHYLATION; PATHOGENESIS; PRIORITY JOURNAL; SEX CHROMOSOME; TROPHOBLASTIC TUMOR; X CHROMOSOME;

EID: 0033945685     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780099     Document Type: Article

References (37)

1. Ariel I, Lustig O, Oyer CE, Elkin M, Gonik B, Rachmilewitz J, Biran H, Goshen R, DeGroot N, and Hochberg A (1994). Relaxation of imprinting in trophoblastic disease. Gynecol Oncol 53:212-219.
2. Arima T, Imamura T, Amada S, Tsuneyoshi M, and Wake N (1994). Genetic origin of malignant trophoblastic neoplasms. Cancer Genet Cytogenet 73:95-102.
3. Arima TI, Sakuragi N, Higashi M, Kamua T, Fujimoto S, Nakano H, and Wake N (1995). Malignant trophoblastic neoplasms with different modes of origin. Cancer Genet Cytogenet 85:5-15.
4. Barlow D (1995). Gametic imprinting in mammals. Science 270:1610-1613.
5. Berkowitz BJ, Jones JG, Merkatz IR, and Runowica CD (1990). Ovarian conservation in placental site trophoblastic tumor. Gynecol Oncol 37:239-43.
6. Chang Y, Chang TC, Hsueh S, Huang KG, Wang PN, Liu HP, and Soong YK (1999). Prognostic factors and treatment for placental site trophoblastic tumor - report of 3 cases and analysis of 88 cases. Gynecol Oncol 73:216-222.
7. Dessau R, Rustin GJS, Dend J, Paradinas FJ, and Bagshawe KD (1990). Surgery and chemotherapy in the management of placental site tumor. Gynecol Oncol 39:56-59.
8. Deveraux QL, Takahashi R, Salvesen GS, and Reed JC (1997). X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-303.
9. Fisher RA, Paradinas FJ, Newlands ES, and Boxer GM (1992). Genetic evidence that placental site trophoblastic tumours can originate from a hydatidiform mole or a normal conceptus. Br J Cancer 65:355-358.
10. Fukunaga M and Ushigome S (1993). Malignant trophoblastic tumors: Immunohistochemical and flow cytometric comparison of choriocarcinoma and placental site trophoblastic tumors. Hum Pathol 24:1098-1106.
11. Glassman M, De Groot N, and Hochberg A (1996). Relaxation of imprinting in carcinogenesis. Cancer Genet Cytogenet 89:69-73.
12. Gloor E, and Harlimann J (1981). Trophoblastic pseudotumor of the uterus, clinicopathologic report with immunohistochemical and ultrastructural studies. Am J Surg Pathol 5:5-13.
13. Goto T, Wright E, and Monk M (1997). Paternal X-chromosome inactivation in human trophoblastic cells. Mol Hum Reprod 3:77-80.
14. Harrison K (1989). X-chromosome inactivation in the human cytotrophoblast. Cytogenet Cell Genet 52:37-41.
15. Harrison K and Warburton D (1986). Preferential X-chromosome activity in human female placental tissues. Cytogenet Cell Genet 41:163-168.
16. Hoffman J, Silverman AD, Gelber J, and Catun R (1993). Placental site trophoblastic tumor: A report of radiologic, surgical and pathologic methods of evaluating the extent of disease. Gynecol Oncol 50:110-114.
17. Jacobs P, Szulman AE, Funkhouser J, Matsuura JA, and Wilson CC (1982). Human triploidy. Relationship between parental origin of the additional haploid complement and development of partial hydatidiform mole. Ann Hum Genet 46:223-231.
18. Janni W, Hantschmann P, Rehbock J, Braun S, Lochmueller E, and Kindermann G (1999). Successful treatment of malignant placental site trophoblastic tumor with combined cytostatic-surgical approach: Case report and review of literature. Gynecol Oncol 75:164-169.
19. Jinno Y, Ikeda Y, Yun K, Maw M, Masuzaki H, Fukuda G, Inuzuka K, Fujishita A, Ohtani Y, Okimoto T, Ishimura T, and Niikawa N (1995). Establishment of functional imprinting of the H19 gene in human developing placentae. Nat Genet 10:318-324.
20. Kajii T and Ohama K (1977). Androgenetic origin of hydatidiform mole. Nature 268:633-634.
21. Kodama S, Kase H, Aoki Y, Yahata T, Tanaka K, Motoyama T, and Kewa K (1996). Recurrent placental site trophoblastic tumor of the uterus: Clinical, pathologic, ultrastructural, and DNA fingerprint study. Gynecol Oncol 60:89-93.
22. Lathrop J, Wachtel FTJ, and Meissner GF (1978). Uterine choriocarcinoma fourteen years following bilateral tubal ligaiton. Obstet Gynecol 51:477-482.
23. Lathrop JL, Lauchlan S, Nayak R, and Ambler M (1988). Clinical characteristics of placental site trophoblastic tumor (PSTT). Gynecol Oncol 31:32-42.
24. Li Y, Lemaire P, and Behringer RR (1997). Esx1, a novel X chromosome-linked homeobox gene expressed in mouse extraembryonic tissues and male germ cells. Dev Biol 88:85-95.
25. Liou J, Pao CC, Hor JJ, and Kao SM (1993). Fetal cells in the maternal circulation during first trimester in pregnancies. Hum Genet 92:309-311.
26. Lin T, Labosky PA, Grabel LB, Kozak CA, Pitman JP, Kleeman J, and MacLeod CL (1994). The Pem homeobox gene is X-linked and exclusively expressed in extraembryonic tissues during early murine development. Dev Biol 166:170-179.
27. Looijenga L, Gillis AJM, Verkerk AJMH, Van Putten WLJ, and Oosterhuis JW (1999). Heterogeneous X inactivation in trophoblastic cells of human full-term female placentas. Am J Hum Genet 64:1445-1452.
28. McGrath JS and Solter D (1984). Completion of mouse embryogenesis requires both the maternal and paternal genomes. Cell 37:179-183.
29. Mutter G, Chaponot ML, and Fletcher JA (1995). A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers. Am J Pathol 146:501-508.
30. Pulford D, Falls JG, Killian JK, and Jirtle RL (1999). Polymorphisms, genomic imprinting and cancer susceptibility. Mutat Res 436:59-67.
31. Rachmilewitz J, Elkin M, Rosensaft J, Gelman-Kohan Z, Ariel I, Lustig O, Schneider T, Goshen R, Biran H, de Groot N, and Hochberg A (1995). H19 expression and tumorigenicity of choriocarcinoma derived cell lines. Oncogene 11:863-870.
32. Redolfi E, Pizzuti A, Di Bacco A, Susani L, Labella T, Affer M, Montagna C, Reinbold R, Mumm S, Vezzoni P, and Zucchi I (1999). Mapping of the MYCL2 processed gene to Xq22-23 and identification of an additional L MYC-related sequence in Xq27.2. FEBS Lett 446:273-277.
33. Ropers J, Wolff F, and Hitzeroth JW (1978). Preferential X inactivation in human placenta membranes: Is the paternal X inactive in early embryonic development of female mammals? Hum Genet 43:265-273.
34. Szulman A (1984). Syndromes of hydatidiform moles, partial VS complete. J Reprod Med 29:788-791.
35. Takagi J and Sasaki M (1975). Preferential inactivation of the paternally derived X chromosome in the extraembryonic membranes of the mouse. Nature 256:640-642.
36. Walsh CM, Miller SJ, Flam F, Fisher RA, and Ohlsson R (1995). Paternally derived H19 is differentially expressed malignant and nonmalignant trophoblast. Cancer Res 55: 1111-1116.
37. Young RH, Kurman RJ, and Scully RE (1988). Proliferations and tumors of intermediate trophoblast of the placental site. Semin Diagn Pathol 5:223-237.